In December 2024, Martin Anderson, Founding Director of Carrot Recruitment, held a round table event which welcomed a cohort of Market Access, RWE and HEOR leaders from the Life Sciences space to discuss: “What does the UK life sciences sector need to change in order to be prioritised more often by global pharma/biotech firms as a leading market for new product launches?”
During the meeting, we discussed themes around:
- How is the UK market currently perceived as a place to launch and why?
- What are the most attractive features of our home market, and conversely, what are the inhibitors?
- How do VPAG and other pricing and reimbursement models impact upon the UK market?
- Does the European JCA (EU HTAR) provide an opportunity for the UK?
- Do the challenges differ for rare disease product launch? Are they the same, but amplified challenges?
- Are regulatory agencies attuned to industry’s increased utilisation of RWE?
- What can be done to improve the situation?
We’d like to extend our thanks to all participants:
- Geoff Dobson, CRS Non-Executive Director, Discussion Chair
- Martin Anderson, Founding Director, Carrot Recruitment
- Tarquin Bennett-Coles, Director, Compass Carter Osborne
- Vladimir Babiy, Associate Director Global Health Economics and Outcomes Research, Novartis
- Judit Banhazi, VP Value & Access, Connect HEOR
- Tijana Ignjatovic, Executive Director Global Market Access & Pricing, Genesis Research Group
- David McConkey, Partner, Access Infinity
- Cristina Sarb, Executive Corporate Affairs Lead, Novartis
- Ross Selby, Value, Access & External Affairs Director, ITF Pharma
- Andrew Smith, UK Market Access Manager, Sun Pharma
- Nyree Sweeney, Executive Director Global Market Access, Menarini
- Oliver Jack, Market Access Lead, Independent
- Aodan Tynan, VP, Head of Global Market Access, Astellas
- Jasim Uddin, Market Access Practice Lead, LCP Health Analytics
To obtain a copy of the full report and the detailed discussions, download your copy below:
In conjunction with The Evidence Base, convening the real-world evidence, health economics and outcomes research communities.
